190 related articles for article (PubMed ID: 36334291)
1. Progesterone receptor expression and prediction of benefits of adjuvant radiotherapy in de novo atypical meningiomas after gross-total resection.
Ren L; Cheng H; Chen J; Deng J; Wang D; Xie Q; Wakimoto H; Hua L; Gong Y
J Neurosurg; 2023 Jul; 139(1):49-58. PubMed ID: 36334291
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes of Newly Diagnosed Resected Atypical Meningiomas and the Role of Adjuvant Radiotherapy.
Zhi M; Girvigian MR; Miller MJ; Chen JC; Schumacher AJ; Rahimian J; Lodin K
World Neurosurg; 2019 Feb; 122():e1153-e1161. PubMed ID: 30447464
[TBL] [Abstract][Full Text] [Related]
3. Skull base atypical meningioma: long term surgical outcome and prognostic factors.
Wang YC; Chuang CC; Wei KC; Hsu YH; Hsu PW; Lee ST; Wu CT; Tseng CK; Wang CC; Chen YL; Jung SM; Chen PY
Clin Neurol Neurosurg; 2015 Jan; 128():112-6. PubMed ID: 25486076
[TBL] [Abstract][Full Text] [Related]
4. Early Postoperative Adjuvant Radiotherapy Versus Active Monitoring After Gross Total Resection for Atypical Meningiomas: Factors Associated with Early Recurrence.
Gurses ME; Zengin HY; Shikhaliyeva A; Askun CS; Mut M
Turk Neurosurg; 2023; 33(4):635-641. PubMed ID: 37470513
[TBL] [Abstract][Full Text] [Related]
5. Early adjuvant radiotherapy in the treatment of atypical meningioma.
Jenkinson MD; Waqar M; Farah JO; Farrell M; Barbagallo GM; McManus R; Looby S; Hussey D; Fitzpatrick D; Certo F; Javadpour M
J Clin Neurosci; 2016 Jun; 28():87-92. PubMed ID: 26775147
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Postoperative Radiotherapy in Patients with Atypical Meningiomas After Gross Total Resection: Analysis of 260 Cases.
Zeng Q; Tian Z; Gao Q; Xu P; Shi F; Zhang J; Guo Z
World Neurosurg; 2022 Jun; 162():e580-e586. PubMed ID: 35307589
[TBL] [Abstract][Full Text] [Related]
7. Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection.
Sun SQ; Kim AH; Cai C; Murphy RK; DeWees T; Sylvester P; Dacey RG; Grubb RL; Rich KM; Zipfel GJ; Dowling JL; Leuthardt EC; Leonard JR; Evans J; Simpson JR; Robinson CG; Perrin RJ; Huang J; Chicoine MR
Neurosurgery; 2014 Oct; 75(4):347-54; discussion 354-5; quiz 355. PubMed ID: 24932707
[TBL] [Abstract][Full Text] [Related]
8. Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma.
Rydzewski NR; Lesniak MS; Chandler JP; Kalapurakal JA; Pollom E; Tate MC; Bloch O; Kruser T; Dalal P; Sachdev S
Cancer; 2018 Feb; 124(4):734-742. PubMed ID: 29131312
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant radiotherapy for atypical meningiomas.
Bagshaw HP; Burt LM; Jensen RL; Suneja G; Palmer CA; Couldwell WT; Shrieve DC
J Neurosurg; 2017 Jun; 126(6):1822-1828. PubMed ID: 27611201
[TBL] [Abstract][Full Text] [Related]
11. Radiopathologic predictors of recurrence in patients with a gross totally resected atypical meningioma.
Anand SK; Sardari H; Sadeghsalehi A; Bagheri SR; Eden SV; Lawton MT; Alimohammadi E
Neurol Res; 2022 May; 44(5):468-474. PubMed ID: 34967283
[TBL] [Abstract][Full Text] [Related]
12. Revisiting Adjuvant Radiotherapy After Gross Total Resection of World Health Organization Grade II Meningioma.
Graffeo CS; Leeper HE; Perry A; Uhm JH; Lachance DJ; Brown PD; Ma DJ; Van Gompel JJ; Giannini C; Johnson DR; Raghunathan A
World Neurosurg; 2017 Jul; 103():655-663. PubMed ID: 28450233
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy in grossly total resected grade II atypical meningiomas: a protective effect on recurrence?
Zoli M; Della Pepa GM; Carretta A; Bongetta D; Somma T; Zoia C; Raffa G
J Neurosurg Sci; 2022 Jun; 66(3):240-250. PubMed ID: 34763391
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.
Chun SW; Kim KM; Kim MS; Kang H; Dho YS; Seo Y; Kim JW; Kim YH; Park CK
Radiat Oncol; 2021 Feb; 16(1):34. PubMed ID: 33596974
[TBL] [Abstract][Full Text] [Related]
15. Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy.
Chen WC; Magill ST; Wu A; Vasudevan HN; Morin O; Aghi MK; Theodosopoulos PV; Perry A; McDermott MW; Sneed PK; Braunstein SE; Raleigh DR
J Neurosurg; 2018 Apr; 130(2):443-450. PubMed ID: 29624151
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with postoperative recurrence in atypical intracranial meningioma: analysis of 263 cases at a single neurosurgical centre.
Wang F; Xu D; Liu Y; Lin Y; Wei Q; Gao Q; Lei S; Guo F
Acta Neurochir (Wien); 2019 Dec; 161(12):2563-2570. PubMed ID: 31641861
[TBL] [Abstract][Full Text] [Related]
17. Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas.
Keric N; Kalasauskas D; Freyschlag CF; Gempt J; Misch M; Poplawski A; Lange N; Ayyad A; Thomé C; Vajkoczy P; Meyer B; Ringel F
J Neurooncol; 2020 Jan; 146(2):347-355. PubMed ID: 31900826
[TBL] [Abstract][Full Text] [Related]
18. Impact of salvage surgery with or without reirradiation for skull base meningiomas recurring after prior radiotherapy.
Rubino F; Schur S; McGovern SL; Kamiya-Matsuoka C; DeMonte F; Raza SM
J Neurosurg; 2023 Sep; 139(3):798-809. PubMed ID: 36738459
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of adjuvant radiotherapy for intracranial atypical and malignant meningiomas.
Unterberger A; Nguyen T; Duong C; Kondajji A; Kulinich D; Yang I
J Neurooncol; 2021 Apr; 152(2):205-216. PubMed ID: 33635510
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma.
Zhu H; Bi WL; Aizer A; Hua L; Tian M; Den J; Tang H; Chen H; Wang Y; Mao Y; Dunn IF; Xie Q; Gong Y
Cancer Med; 2019 Jan; 8(1):13-20. PubMed ID: 30680963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
